Sean Stalfort is a founding Partner and President of PBM Capital. Since 2010, Sean has been a Board member and/or founding investor in over 10 companies which went public or were acquired, including AveXis (acquired by Novartis for $8.7 billion), Archer (acquired by Invitae for $1.4 billion), Dova (acquired by Sobi for over $900 million), Taysha Gene Therapies (NASDAQ: TSHA), Candel Therapeutics (NASDAQ: CADL), Verrica Pharmaceuticals (NASDAQ: VRCA), and Acumen Therapeutics (NASDAQ: ABOS). Prior to joining PBM Capital, Sean was the Executive Vice President for New Business Development and M&A for PBM Products which was sold to Perrigo Company (NASDAQ: PRGO) for over $800 million. Sean began his career in finance at First Boston and Greenwich Capital Markets. He received his BA in Business Economics from Brown University.